Psychedelics Policy Is Shifting In Washington: Here's What One Biotech CEO Sees Coming - Cybin (AMEX:CYBN)

An international Delphi consensus for reporting of setting in psychedelic clinical trials

Psychedelic substances exhibit complex interactions with the ‘set and setting’ of use, that is, the mental state of the user and the environment in which a psychedelic experience takes place. Despite these contextual variables’ known importance, psychedelic research has lacked methodological rigor in reporting extra-pharmacological factors. This study aimed to generate consensus-based guidelines for reporting settings in psychedelic clinical res…

Clinical research on psychedelics gets a boost from new study

As psychedelics gain traction as potential treatments for mental health disorders, an international study stands to improve the rigor and reliability of clinical research.

Psychedelics Policy Is Shifting In Washington: Here's What One Biotech CEO Sees Coming - Cybin (AMEX:CYBN)

Federal support for psychedelics is rising fast. One biotech CEO explains what it means for clinical trials, access, and real-world therapy.

Study Explores Psychedelics’ Role in Reducing PTSD Symptoms Among Survivors of October 7 Nova Festival Attack

A recent study conducted by researchers at Reichman Uni […] The post Study Explores Psychedelics’ Role in Reducing PTSD Symptoms Among Survivors of October 7 Nova Festival Attack first appeared on GeneOnline News. The post Study Explores Psychedelics’ Role in Reducing PTSD Symptoms Among Survivors of October 7 Nova Festival Attack appeared first on GeneOnline News.

Study: Aesthetic Elements of Psychedelic Experiences Strongly Linked to Psychological Benefits

The Marijuana Herald - Marijuana news and information A new study finds that the aesthetic quality of psychedelic experiences—such as vivid visual imagery and emotional beauty—may be a key factor in promoting therapeutic benefits. Researchers at the University of Colorado surveyed 96 individuals who had used classic psychedelics like psilocybin, LSD, DMT, or mescaline within the past year. Participants completed several psychological assessments…